Contenido principal del artículo

Resumen

En diciembre de 2019 se identificó en China una nueva subespecie de coronavirus al que denominaron SARS-CoV-2, responsable de la enfermedad posterior a la que la OMS llamó COVID-19. La enfermedad se ha propagado rápidamente provocando una pandemia mundial. Todavía se desconoce mucho del SARS-CoV-2, pero las primeras investigaciones respaldan la hipótesis de que la gravedad de la COVID-19 viene condicionada por la respuesta hiperinflamatoria que se produce en nuestro organismo al contacto con el SARS-CoV-2. La gravedad del cuadro se relaciona con la insuficiencia respiratoria que provoca, no obstante, existen estudios que no limitan la afectación pulmonar. Investigaciones apuntan a que el mecanismo de acceso del SARS-CoV-2 al organismo está muy relacionado con la enzima ACE2. Enzima que entre otros tejidos, se puede encontrar en el epitelio de las células tubulares renales. Esta es la causa por la que existen datos de pacientes con COVID-19 que tienen una gran afectación en la función renal y pueden cursar con IRA (factor de mal pronóstico). Por este motivo, unido a que las comorbilidades asociadas con una mayor mortalidad durante la infección COVID-19 son comunes en los pacientes con enfermedad renal crónica, creemos necesario conocer los resultados que aportan los diferentes estudios realizados sobre esa materia.

Palabras clave

COVID-19 SARS-CoV-2 enfermedades renales revisión diálisis trasplante riñón

Detalles del artículo

Cómo citar
1.
Hidalgo-Blanco M Ángel, Andreu-Periz D, Moreno-Arroyo MC. COVID-19 en el enfermo renal. Revisión breve. Enferm Nefrol [Internet]. 28 de mayo de 2020 [citado 13 de junio de 2021];23(2):122-31. Disponible en: https://enfermerianefrologica.com/revista/article/view/3534

Referencias

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
  2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb;395(10224):565-74.
  3. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38.
  4. Li-sheng Wang , Yi-ru Wang , Da-wei Ye , Qing-quan Liu. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020 Mar:105948. [En prensa].
  5. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020 Feb. [En prensa].
  6. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe. 2020 Feb;27(3):325-8.
  7. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021.
  8. Michaels MG, La Hoz RM, Danziger-Isakov L, Blumberg EA, Kumar D. Green M, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020 Feb. [En prensa].
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
  10. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. On behalf of the “Brescia Renal COVID Task Force, Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy. Kidney Int Rep. 2020 Abr. [En prensa].
  11. Wei LQ, Rong ZK, Gui L, Shan RD. CT diagnosis of renal vein thrombosis in nephrotic syndrome. J Comput Assist Tomogr. 1991;15(3):454-7.
  12. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.
  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar;395(10229):1033-4.
  14. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Abr;383(9927):1503-16.
  15. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 2019;10:55.
  16. Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 2016;149:1294-301.
  17. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223): 473-5.
  18. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9)2613-20.
  19. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARSCoV- 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.
  20. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar; 367(6485):1444-8.
  21. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARSCoV- 2. J Med Virol. 2020 Feb. [En prensa].
  22. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Feb;367(6483):1260-3.
  23. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20.
  24. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457-60.
  25. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Mar. [En prensa].
  26. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006 Nov;17(11):3067-75.
  27. Wang L, Li X, Chen H, Yan S, Li D, Li Y, Gong Z. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-8.
  28. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 N Engl J Med. 2020;382:1653-9.
  29. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus- Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
  30. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382:1708-20.
  31. Rabb H. Kidney diseases in the time of COVID-19: major challenges to patientcare. J Clin Invest. 2020 May. pii: 138871. [En prensa].
  32. Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, et al. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv. 2020 Mar. [En prensa].
  33. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv. 2020 Feb. [En prensa].
  34. Zhang WR, and Parikh CR. Biomarkers of Acute and Chronic Kidney Disease. Annu Rev Physiol. 2019;81:309-33.
  35. Ma Y, Diao B, Lv X, Zhu J, Liang W, Wendou LL, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. medRxiv. 2020 Feb. [En prensa].
  36. Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. Am J Kidney Dis. 2020 Mar. pii: S0272-6386(20)30612-0. [En prensa].
  37. Guillen E, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M, Moreno A, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?. Am J Transplant. 2020 Mar. [En prensa].
  38. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Antoni AD, et al. COVID-19 in Kidney Transplant Recipients. Am J Transplant. 2020;10.1111/ajt.15891. [En prensa].
  39. Zhu L, Xu X, Ma K, Yang K, Guan H, Chen S, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020 Mar. [En prensa].
  40. Cohen-Hagai K, Rozenberg I, Korzets Z, Zitman-Gal T, Einbinder Y, Benchetrit S. Upper Respiratory Tract Infection among Dialysis Patients. Isr Med Assoc J. 2016;18:557-60.
  41. Sibbel S, Sato R, Hunt A, Tuernne W, Brurnelli SM. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study. BMC Nephrol. 2016;17:199.
  42. Trujillo H, Caravaca-Fontán F, Sevillano Á, Gutiérrez E, Caro J, Gutiérrez E, et al. SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease. Kidney Int Rep. May 2020. [En prensa].
  43. Rombolà G, Brunini F. COVID-19 and dialysis: why we should be worried. J Nephrol. 2020 Abr;22:1-3.
  44. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824-28.
  45. Brodie D, Curtis JR, Vincent JL, Bakker J, Brown CE, Creteur J, et al. Participants in the Round Table Conference. Treatment limitations in the era of ECMO. Lancet Respir Med. 2017 Oct;5(10):769-70.
  46. Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011 Oct; 306(15):1659-68.
  47. DeLaney E, Smith MJ, Harvey BT, Pelletier KJ, Aquino MP, Stone JM, et al. Extracorporeal life support for pandemic influenza: the role of extracorporeal membrane oxygenation in pandemic management. J Extra Corpor Technol. 2010 Dic;42(4):268-80.
  48. Lim CC, Tan CS, Kaushik M, Tan HK. Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study. Nephrology (Carlton). 2015;20:148-54.
  49. Rombolà G, Heidempergher M, Pedrini L, Farina M, Aucella F, Messa P, et al. Practical indications for the prevention and management of SARS-CoV2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy. J Nephrol. 2020 Abr;33(2):193-6.
  50. Ikizler TA. COVID-19 and dialysis units: what do we know now and what should we do?. Am J Kidney Dis. 2020 Mar. [En prensa].
  51. Bomback AS, Canetta PA, Ahn W, Ahmad SB, Radhakrishnan J, Appel GB. How COVID-19 Has Changed the Management of Glomerular Diseases. CJASN. 2020 May. [En prensa].
  52. Bussalino E, De Maria A, Russo R, Paoletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report. Am J Transplant. 2020 Abr. [En prensa].
  53. Michaels MG, La Hoz RM, Danziger-Isakov L, Blumberg EA, Kumar D, Green M, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020 Feb. [En prensa].
  54. Alberici F, Delbarba E, Manenti C, Econimo L Valerio F, Pola A, et al. Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy. Kidney Int Rep. 2020 Abr. [En prensa].
  55. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020 Abr. [En prensa].
  56. Liu B1, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. Am J Transplant. 2020 Abr. [En prensa].
  57. Seminari E, Colaneri M, Sambo M, Gallazzi I, Di Matteo A, Roda S, et al. SARS Cov2 infection in a renal transplanted patients. A case report. Am J Transplant. 2020 Abr. [En prensa].
  58. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020 Mar. [En prensa].
  59. 59. Chen S, Yin Q, Shi H, Du D, Chang S, Ni L, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020 Abr. [En prensa].
  60. 60. Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. COVID-19 in post-transplantation patients - report of two cases. Am J Transplant. 2020 Abr. [En prensa].
  61. 61. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube G, Ratner LE, et al., COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US epicenter. Am J Transplant. 2020 Abr. [En prensa].
  62. 62. Antonio R, Silvia M. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical hypothesis. Am J Transplant. 2020 Abr. [En prensa].
  63. 63. Fishman, J.A. Infection in Organ Transplantation. Am J Transplant 2017;17(4): 856-79.
  64. 64. Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression. Pharmacotherapy. 2020;10.1002/phar.2410. [En prensa].